Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Paying user area


We accept:

Visa Mastercard Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check

Short-term Activity Ratios (Summary)

Pfizer Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Turnover Ratios
Inventory turnover
Receivables turnover
Payables turnover
Working capital turnover
Average No. Days
Average inventory processing period
Add: Average receivable collection period
Operating cycle
Less: Average payables payment period
Cash conversion cycle

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).


A comprehensive analysis of the operating activity ratios reveals a significant lengthening of the working capital cycle and a general decline in asset turnover efficiency over the observed period. The overall trend indicates a slower movement of inventory and an increase in the time required to convert current assets into cash.

Inventory Management
A consistent downward trend in inventory turnover is evident, declining from 3.67 in April 2022 to 1.72 by June 2026. This decline is mirrored by the average inventory processing period, which expanded from 99 days to a peak of 251 days in September 2025, before moderating to 212 days. This suggests a substantial accumulation of stock or a reduction in the velocity of product sales.
Receivables and Collection Efficiency
Receivables turnover shows a general decrease, falling from 6.99 in early 2022 to 5.10 in June 2026. Consequently, the average receivable collection period increased from 52 days to 72 days. This trend indicates a slower recovery of credit sales, implying that capital is remaining tied up in accounts receivable for longer durations.
Payables and Supplier Terms
The payables turnover ratio decreased from 6.66 to 3.73, while the average payables payment period extended from 55 days to 98 days. This trend indicates that the company is taking longer to settle its obligations to suppliers, which serves as a mechanism to partially offset the liquidity pressures caused by slower inventory and receivable turnovers.
Operating and Cash Conversion Cycles
The operating cycle experienced a marked expansion, rising from 151 days in April 2022 to a peak of 334 days in September 2025, ending at 284 days. The cash conversion cycle followed a similar trajectory, increasing from 96 days to a peak of 224 days in September 2025, and concluding at 186 days. The overall extension of the cash conversion cycle signifies a decrease in operational liquidity and an increase in the need for working capital financing.
Working Capital Turnover
The working capital turnover ratio exhibits extreme volatility, with a notable anomaly occurring in September 2024. Excluding this outlier, the ratio fluctuates significantly, reflecting instability in the relationship between net working capital and net sales throughout the period.

Turnover Ratios


Average No. Days


Inventory Turnover

Pfizer Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Inventories
Short-term Activity Ratio
Inventory turnover1
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Inventory turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Inventories
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term activity ratios reveals a significant long-term decline in inventory efficiency, followed by a modest recovery in the final periods of the observed timeframe.

Inventory Turnover Ratio Trend
The inventory turnover ratio exhibited a consistent downward trajectory from a peak of 3.82 in December 2022 to a low of 1.46 in June 2025. This represents a substantial reduction in the frequency with which inventory is replaced. A slight reversal is observed between September 2025 and June 2026, where the ratio recovered to 1.72.
Cost of Sales Volatility
Cost of sales displayed significant quarterly fluctuations throughout the period. High values were prevalent in 2022, with a peak of 9,984 million USD in April 2022. A sharp contraction occurred in early 2023, reaching a low of 3,237 million USD in July 2023, followed by a temporary surge in late 2023. From 2024 through 2026, the cost of sales generally stabilized within a lower range, typically between 2,845 million USD and 5,909 million USD.
Inventory Level Dynamics
Inventory levels remained relatively stable during 2022 but entered a growth phase throughout 2023 and 2024. Total inventories reached a peak of 11,721 million USD in September 2024. Following this peak, inventory levels gradually declined, returning to 9,945 million USD by June 2026.
Operational Efficiency Correlation
The degradation of the turnover ratio is primarily attributable to the simultaneous occurrence of declining cost of sales and increasing inventory holdings. The period of lowest efficiency between 2024 and mid-2025 coincides with the peak of inventory accumulation. The subsequent improvement in the ratio toward June 2026 is linked to the reduction of total inventory levels while costs of sales remained relatively steady.

Receivables Turnover

Pfizer Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Revenues
Trade accounts receivable, net of allowance for doubtful accounts
Short-term Activity Ratio
Receivables turnover1
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Receivables turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Trade accounts receivable, net of allowance for doubtful accounts
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


An analysis of the receivables turnover reveals a general decline in the efficiency of credit collection over the period from April 2022 to June 2026. While the company exhibited high turnover rates in 2022, a subsequent trend toward lower ratios suggests a slowing of the cash conversion cycle for accounts receivable.

Peak and Initial Volatility
The highest efficiency was recorded on December 31, 2022, with a receivables turnover ratio of 9.16. This period marked a significant spike compared to the earlier quarters of 2022, where the ratio fluctuated between 6.21 and 6.99.
Downward Trend and Revenue Correlation
A consistent downward trajectory is observed throughout 2023 and much of 2024. The ratio fell from 7.57 in April 2023 to a period low of 4.18 by September 2024. This deterioration in turnover correlates with a broader contraction in quarterly revenues, which declined from peaks exceeding 27 billion USD in 2022 to a range between 13 billion and 17 billion USD in subsequent years.
Stabilization Period
From December 2024 through June 2026, the receivables turnover ratio entered a stabilization phase, fluctuating within a tighter range between 4.40 and 5.55. This indicates that while efficiency did not return to 2022 levels, the collection cycle reached a new, consistent operational baseline.

Payables Turnover

Pfizer Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Cost of sales
Trade accounts payable
Short-term Activity Ratio
Payables turnover1
Benchmarks
Payables Turnover, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Payables turnover = (Cost of salesQ2 2026 + Cost of salesQ1 2026 + Cost of salesQ4 2025 + Cost of salesQ3 2025) ÷ Trade accounts payable
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a significant and sustained downward trend in the payables turnover ratio over the observed period. This trajectory indicates a slowing frequency in the settlement of trade obligations relative to the cost of sales, suggesting an extension of the average payment period to suppliers.

Payables Turnover Evolution
The payables turnover ratio began at a high of 6.66 in April 2022 and experienced a steady decline throughout the remainder of that year, closing at 5.04 in December 2022. This downward trend persisted through 2023 and 2024, reaching a periodic low of 3.07 by December 2024. Although the ratio showed a modest recovery toward 3.73 by June 2026, it remained substantially lower than the levels recorded in the initial phase of the analysis.
Correlation Between Cost of Sales and Payables
The volatility in the turnover ratio is closely linked to fluctuations in the cost of sales. High-cost periods, such as October 2023, saw temporary spikes in turnover (5.07), whereas periods of lower operating costs in 2024 and 2025 contributed to the ratio dipping toward the 3.0 to 3.4 range. Meanwhile, trade accounts payable remained relatively stable, generally fluctuating between 4,500 million and 6,800 million. Because the payable balances did not decrease proportionally with the cost of sales in later periods, the turnover ratio declined.
Operational Implications
The shift from a turnover ratio of 6.66 to a stabilized range between 3.0 and 3.7 suggests a change in working capital management. A lower turnover ratio implies that cash is being retained longer within the organization before being disbursed to vendors. This trend may reflect a strategic decision to optimize liquidity or a renegotiation of credit terms with suppliers to extend payment windows.

Working Capital Turnover

Pfizer Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data (US$ in millions)
Current assets
Less: Current liabilities
Working capital
 
Revenues
Short-term Activity Ratio
Working capital turnover1
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Working capital turnover = (RevenuesQ2 2026 + RevenuesQ1 2026 + RevenuesQ4 2025 + RevenuesQ3 2025) ÷ Working capital
= ( + + + ) ÷ =

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a period of significant volatility in working capital management and revenue generation, followed by a transition toward stabilization. The relationship between current operating liquidity and revenue production experienced extreme fluctuations between 2022 and 2024, before entering a more consistent phase from 2025 through mid-2026.

Revenue Performance Trends
A distinct contraction in quarterly revenues is observed starting from early 2022, where figures peaked between 25.6 billion and 27.7 billion US dollars. A downward shift occurred throughout 2023, with revenues reaching lows of approximately 13 billion US dollars. From 2024 through 2026, revenues demonstrated a moderate recovery and stabilization, generally oscillating between 13.7 billion and 17.7 billion US dollars.
Working Capital Volatility
Working capital exhibited extreme instability. After an initial increase that peaked at 42.8 billion US dollars in October 2023, the metric experienced a sharp decline, entering negative territory in December 2023 (-4.4 billion US dollars) and June 2024 (-5.9 billion US dollars). This indicates periods where current liabilities exceeded current assets. Starting in late 2024, working capital returned to positive values and stabilized within a range of 5.9 billion to 10.3 billion US dollars.
Working Capital Turnover Analysis
The working capital turnover ratio mirrored the volatility of the underlying components. Between April 2022 and October 2023, the ratio declined from 6.10 to a low of 1.62, signaling a decrease in the efficiency of using working capital to generate sales as the capital base expanded while revenues fell. During the periods of near-zero or negative working capital in 2024, the ratio produced mathematical anomalies, including a spike to 5,036.00 in September 2024, which renders the ratio non-indicative of operational efficiency during those specific intervals.
Normalization Phase
A period of stabilization is evident from March 2025 through June 2026. During this window, the working capital turnover ratio fluctuated within a professional operating range of 6.08 to 10.68. This suggests a more sustainable and predictable alignment between the company's short-term asset-liability structure and its revenue-generating capacity.

Average Inventory Processing Period

Pfizer Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Inventory turnover
Short-term Activity Ratio (no. days)
Average inventory processing period1
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An analysis of the short-term operating activity ratios reveals a significant deterioration in inventory management efficiency beginning in early 2023, followed by a modest recovery trend toward the end of the observed period.

Inventory Turnover Trends
Between April 2022 and December 2022, inventory turnover remained relatively stable, peaking at 3.82. However, a consistent downward trajectory began in April 2023, where the ratio fell to 3.07, eventually reaching a minimum of 1.46 by September 2025. This decline represents a substantial reduction in the frequency with which inventory is replaced. A slight reversal of this trend is observed in the final three quarters, with the ratio improving to 1.72 by June 2026.
Average Inventory Processing Period Trends
The average inventory processing period exhibits an inverse correlation with turnover ratios. For the 2022 calendar year, the period remained consistent, fluctuating between 95 and 101 days. Starting in April 2023, there was a sharp increase in the time required to process inventory, rising to 119 days and continuing a steep climb throughout 2024. The processing period peaked at 251 days in September 2025, indicating that inventory remained stagnant for significantly longer durations. A gradual reduction is noted thereafter, ending at 212 days in June 2026.
Operational Efficiency Analysis
The data indicates a period of operational inefficiency characterized by a prolonged buildup of inventory or a deceleration in sales velocity starting in the second quarter of 2023. The expansion of the processing period from approximately 100 days to over 250 days suggests a significant increase in carrying costs and potential liquidity constraints. While the most recent data points suggest a correction is underway, the processing period remains more than double the baseline levels observed in 2022.

Average Receivable Collection Period

Pfizer Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Receivables turnover
Short-term Activity Ratio (no. days)
Average receivable collection period1
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


The analysis of operating activity ratios indicates a general deterioration in the efficiency of receivable collections over the observed period from April 2022 to June 2026.

Receivables Turnover Trends
A predominantly downward trend is observed in the receivables turnover ratio following a peak of 9.16 in December 2022. The ratio declined steadily over the subsequent two years, reaching a low of 4.18 by September 2024. Although a slight recovery was noted through 2025, the ratio stabilized at 5.10 by June 2026, representing a significant decrease in the frequency of receivable conversion compared to the 2022 baseline.
Average Receivable Collection Period Analysis
The average receivable collection period exhibits an inverse relationship with turnover, showing a marked increase in the duration required to collect outstanding payments. The collection cycle was most efficient in December 2022, requiring only 40 days. This period subsequently expanded, peaking at 87 days in September 2024. From December 2024 through June 2026, the collection period remained elevated, fluctuating between 66 and 83 days, indicating a persistent slowdown in cash inflows from customers.
Operational Implications
The expansion of the collection period from 40 days to a range of 72-73 days by mid-2026 suggests a shift in credit management or a decrease in customer payment promptness. This extension of the cash conversion cycle indicates that a larger portion of capital is tied up in receivables for longer durations, which may impact short-term liquidity and increase the company's exposure to credit risk over the long term.

Operating Cycle

Pfizer Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Short-term Activity Ratio
Operating cycle1
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc.
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =

2 Click competitor name to see calculations.


The operating cycle exhibits a significant long-term expansion, indicating a slowing in the conversion of operational inputs into cash. The cycle began at 151 days in April 2022 and reached a peak of 334 days by September 2025, before moderately contracting to 284 days by June 2026.

Average Inventory Processing Period
A pronounced upward trend is observed in the time required to process inventory. The period remained relatively stable around 100 days throughout 2022 but began a steep ascent in early 2023. The processing period more than doubled, rising from 119 days in April 2023 to a peak of 251 days in September 2025. While a gradual decline occurred in the final three quarters, ending at 212 days in June 2026, the period remains substantially higher than the 2022 baseline.
Average Receivable Collection Period
The collection period demonstrates increased volatility and a general upward trajectory. After fluctuating between 40 and 59 days in 2022, the collection timeframe shifted to a higher range, peaking at 87 days in September 2024. In the subsequent periods, the collection period stabilized between 66 and 83 days. This suggests a general lengthening of the time required to collect payments from customers compared to the start of the observed period.
Operating Cycle Synthesis
The expansion of the total operating cycle is primarily driven by the deterioration of inventory turnover. The inventory processing period contributes the vast majority of the increase in the cycle length. The peak in the operating cycle in September 2025 corresponds directly with the maximum recorded inventory processing time. The slight reduction in the operating cycle toward mid-2026 is attributed to simultaneous improvements in both inventory processing and receivable collection periods.

Average Payables Payment Period

Pfizer Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Payables turnover
Short-term Activity Ratio (no. days)
Average payables payment period1
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =

2 Click competitor name to see calculations.


An analysis of the operating activity ratios reveals a consistent trend toward the extension of the time required to settle obligations with suppliers. This is evidenced by a steady increase in the average payables payment period coupled with a corresponding decline in the payables turnover ratio over the observed period from April 2022 to June 2026.

Payables Turnover
A sustained downward trajectory is observed in the payables turnover ratio, which declined from a peak of 6.66 in April 2022 to 3.73 by June 2026. The ratio experienced its most significant contraction between April 2022 and December 2023, dropping to 3.72. A further low of 3.17 was reached in December 2024, suggesting a marked reduction in the frequency with which accounts payable are cleared relative to the costs of goods sold.
Average Payables Payment Period
The period required to pay suppliers shifted from a relatively short duration of 55 days in April 2022 to a peak of 119 days in December 2025. The progression shows a phased increase: the period rose to 72 days by the end of 2022, reached 98 days by the end of 2023, and climbed to 115 days by the end of 2024. Following the peak in late 2025, the payment period contracted and stabilized at 98 days during the first half of 2026.
Working Capital Implications
The inverse relationship between the turnover ratio and the payment period indicates a strategic shift in working capital management. The extension of the payment cycle, which more than doubled between April 2022 and December 2025, suggests an increase in the utilization of supplier credit to preserve cash liquidity. The stabilization observed in 2026 suggests a transition toward a new baseline for supplier payment terms.

Cash Conversion Cycle

Pfizer Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Jun 28, 2026 Mar 29, 2026 Dec 31, 2025 Sep 28, 2025 Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022
Selected Financial Data
Average inventory processing period
Average receivable collection period
Average payables payment period
Short-term Activity Ratio
Cash conversion cycle1
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-Q (reporting date: 2026-06-28), 10-Q (reporting date: 2026-03-29), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-28), 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03).

1 Q2 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + =

2 Click competitor name to see calculations.


The overall operating efficiency reflects a significant expansion of the cash conversion cycle over the observed period. While the cycle remained relatively stable under 100 days throughout 2022, it entered a period of sustained growth starting in early 2023, peaking at 224 days in September 2025 before moderating slightly to 186 days by June 2026. This indicates a substantial increase in the time required to convert resource inputs into cash flows from sales.

Average Inventory Processing Period
A pronounced upward trend is observed in inventory management. Processing times remained consistent around 100 days in 2022 but began a steep ascent in April 2023 (119 days), ultimately reaching a peak of 251 days in September 2025. Although a slight reduction to 212 days occurred by June 2026, the period remains more than double the 2022 baseline, suggesting a significant accumulation of inventory or a slowdown in product turnover.
Average Receivable Collection Period
The collection of receivables demonstrates moderate volatility with a general upward trajectory. After a low of 40 days in December 2022, the collection period generally trended higher, peaking at 87 days in September 2024. The period concluded at 72 days in June 2026. This suggests a gradual decline in the efficiency of credit collection or a shift in customer payment terms.
Average Payables Payment Period
The company has systematically extended its payment terms to suppliers. The payment period rose from 55 days in April 2022 to a peak of 119 days in December 2025. This expansion in payables serves as a critical financing mechanism, partially offsetting the liquidity pressures caused by the slowing inventory turnover and slower receivable collections.
Cash Conversion Cycle Synthesis
The expansion of the cash conversion cycle is primarily driven by the deterioration of inventory processing efficiency. The significant increase in the inventory period far outweighed the mitigating effect of the extended payables payment period. Consequently, the business has experienced an increase in working capital requirements, with the cycle lengthening from a low of 63 days in December 2022 to a peak of 224 days in September 2025.